The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
951
June 23, 1995
View Complete Issue         Table of Contents 2019 
Varicella Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Varicella Vaccine
June 23, 1995 (Issue: 951)
A live attenuated varicella vaccine (Varivax - Merck) has been approved for marketing by the US Food and Drug Administration. The Oka/Merck strain used in the vaccine is attenuated by passage in human and embryonic guinea pig cell cultures.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Varicella Vaccine
Article code: 951a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.